Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191542 | 0.85 | EPHX2 (0.39) | EPHX2PDE2ASLC7A5 | |
| SCHEMBL621959 | 0.84 | EPHX2 (0.33) | EPHX2PDE2A | |
| SCHEMBL1069020 | 0.81 | HSD11B1 (0.34) | EPHX2 | |
| SCHEMBL146485 | 0.79 | SLC1A5 (0.34) | EPHX2 | |
| SCHEMBL12504933 | 0.79 | PDE2A (0.35) | EPHX2PDE2A | |
| SCHEMBL145670 | 0.79 | EPHX2 (0.31) | EPHX2 | |
| SCHEMBL27973620 | 0.79 | PDE2A (0.32) | EPHX2PDE2A | |
| SCHEMBL2439618 | 0.79 | EPHX2 (0.31) | EPHX2 | |
| SCHEMBL1068712 | 0.79 | SCN5A (0.33) | EPHX2PDE2A | |
| SCHEMBL7685103 | 0.79 | KCNN4 (0.42) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073283-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | claimed |
| EP-4304585-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | claimed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | claimed |
| EP-4144739-A1 | ANELLATED PYRAZOLES AS PARASITICIDES | Bayer Aktiengesellschaft (DE) | 2023-03-08 | — | — | EP | claimed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | claimed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | claimed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | claimed |
| EP-2049500-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | claimed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | claimed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008006032-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | claimed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | KUREHA CORPORATION (JP) | 2004-08-05 | — | — | US | claimed |
| EP-1375483-A1 | 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | claimed |
| US-5045566-A | Phenyl or naphthyl substituted | ICI AMERICAS INC. (US) | 1991-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | EPHX2 4021/4885PDE2A 1589/4885SLC7A5 2569/4885 |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN2A | EPHX2 4378/4885PDE2A 545/4885SLC7A5 2261/4885 |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | EPHX2 2196/4885PDE2A 2739/4885SLC7A5 758/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | EPHX2 2203/4885PDE2A 1813/4885SLC7A5 1887/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | EPHX2 2087/4885PDE2A 3259/4885SLC7A5 3169/4885 |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | PGLS, TLR6, UROD | EPHX2 1579/4885PDE2A 1783/4885SLC7A5 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.